



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Norman NASHED et al.

Serial No.: 09/619,493

Group Art Unit: 1616

Filed: July 19, 2000

Examiner: S.N. Qazi

For: THERAPEUTIC GESTAGENS FOR THE TREATMENT OF PREMENSTRUAL
DYSPHORIC DISORDER

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97
and 1.98 as follows:

Timing and Fees

- ☐ Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information
disclosure statement is filed:
- ☐ within three months of the filing date of a national application other than a CPA
under § 1.53(d);
 - ☐ within three months of the actual filing date of the national phase of a PCT
application; OR
 - ☐ before the mailing of a first substantive office action (including after filing of an
RCE).
- ☒ Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods
specified in 37 C.F.R. § 1.97(b), but before the mailing date of:
- ☒ a final rejection under 37 C.F.R. 1.113;
 - ☐ termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
OR
 - ☐ a notice of allowance under 37 C.F.R. § 1.311; and

RECEIVED

MAY 22 2003
TECH CENTER 1600/2900


#27

RECEIVED

OCT 15 2003

TECH CENTER 1600/2900

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number 09/619,493
Filing Date July 19, 2000
First Named Inventor N. NASHED et al.
Group Art Unit 1616
Examiner Name S.N. Qazi
Attorney Docket Number SCH 1686 C1

RECEIVED

OCT 15 2003

TECH CENTER 1600/2900

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B1	E. Freeman et al., <i>Evaluation of a Unique Oral Contraceptive in the Treatment of Premenstrual Dysphoric Disorder</i> , Journal of Women's Health & Gender-Based Medicine, Vol. 10, No. 6, 2001, pp. 561-569	
	B2	E. Freeman et al., <i>A Double-blind Trial of Oral Progesterone, Alprazolam, and Placebo in Treatment of Severe Premenstrual Syndrome</i> , JAMA, Vol. 274, No. 1, July 5, 1995, pp. 51-57	
	B3	P.M. 'Brien et al., <i>Treatment of Premenstrual Syndrome by Spironolactone</i> , British Journal of Obstetrics and Gynaecology, Vol. 86, February 1979, pp. 142-147	
	B4	D. Hellberg et al., <i>Premenstrual tension: a placebo-controlled efficacy study with spironolactone and medroxyprogesterone acetate</i> , Int. J. Gynecol. Obstet., 1991; 34: pp. 243-248	
	B5	M. Wang et al., <i>Treatment of premenstrual syndrome by spironolactone: A double-blind, placebo-controlled study</i> , Acta Obstet Gynecol Scand. 1995: 74: pp. 803-808	
	B6	R.B. Burnet et al., <i>Premenstrual Syndrome and Spironolactone</i> , Aust NZ J. Obstet Gynaecol 1991; 31: 4: 366	
	B7	K. Aslaksen et al., <i>Spironolactone in the Treatment of Premenstrual Tension: A Double-Blind Study of Spironolactone Versus Bendroflumethiazide and Placebo</i> , Current Therapeutic Research, Vol. 49, No. 1, January 1991, pp. 120-130	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.